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ABSTRACT: The rapidly growing COVID-19 pandemic is the most
serious global health crisis since the “Spanish flu” of 1918. There is
currently no proven effective drug treatment or prophylaxis for this
coronavirus infection. While developing safe and effective vaccines is one of
the key focuses, a number of existing antiviral drugs are being evaluated for
their potency and efficiency against SARS-CoV-2 in vitro and in the clinic.
Here, we review the significant potential of nitazoxanide (NTZ) as an
antiviral agent that can be repurposed as a treatment for COVID-19.
Originally, NTZ was developed as an antiparasitic agent especially against
Cryptosporidium spp.; it was later shown to possess potent activity against a broad range of both RNA and DNA viruses, including
influenza A, hepatitis B and C, and coronaviruses. Recent in vitro assessment of NTZ has confirmed its promising activity against
SARS-CoV-2 with an EC50 of 2.12 μM. Here we examine its drug properties, antiviral activity against different viruses, clinical trials
outcomes, and mechanisms of antiviral action from the literature in order to highlight the therapeutic potential for the treatment of
COVID-19. Furthermore, in preliminary PK/PD analyses using clinical data reported in the literature, comparison of simulated TIZ
(active metabolite of NTZ) exposures at two doses with the in vitro potency of NTZ against SARS-CoV-2 gives further support for
drug repurposing with potential in combination chemotherapy approaches. The review concludes with details of second generation
thiazolides under development that could lead to improved antiviral therapies for future indications.
KEYWORDS: COVID-19, SARS-CoV-2, coronavirus, antiviral, pharmacokinetics, nitazoxanide, tizoxanide
■ INTRODUCTION
When reports of a few cases of a new strain of pneumonia
caused by an unknown pathogen were reported in Wuhan, a
city of central China, in December 2019, there was little
international concern.1 A few weeks later almost 3000 cases,
leading to 81 deaths, had already been recorded in China, and
the disease had spread not merely to other areas of Asia but
also to Europe, North America, and Australia.2 By then the
pathogen responsible for cases of pneumonia had been
identified as a novel strain of coronavirus, which was named
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2), that bears a close resemblance to the severe acute
respiratory syndrome (SARS) virus responsible for outbreaks
of disease in 2002−2003.3 At the time of writing (late
November 2020), over 53 million cases of the COVID-19
infection have been reported worldwide with over 1.35 million
deaths.4
This rapidly growing pandemic is widely regarded as the
most serious global health crisis since the “Spanish flu” of
1918. Currently, there is no proven effective small molecule
treatment or prophylaxis for the disease although a number of
them have been reviewed.5 Many groups are actively searching
for an effective vaccine and a number of them have entered late
stage (phase 3) clinical trials with some very positive results as
of the end of November 2020.6,7 Early small molecule
screening reported by Wang8 revealed several hit molecules
in vitro with a focus on the known antiviral remdesivir (1)9,10
and the 4-aminoquinoline antimalarial chloroquine (2),11,12
which were the main focus of this seminal publication.
Subsequently, multiple clinical trials have commenced with
remdesivir, chloroquine, and the related hydroxychloroquine
(3),13 a drug used for autoimmune diseases such as
rheumatoid arthritis and systemic lupus erythematosus (Figure
1).
In this review, we concentrate on the significant potential of
nitazoxanide, 2-(acetyloxy)-N-(5-nitro-2-thiazolyl) benzamide
(NTZ, 4), as a broad spectrum antiviral agent against COVID-
19. NTZ, initially developed as an antiparasitic agent especially
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against Cryptosporidium spp.,14 was later shown to have broad-
spectrum antiviral activity15,16 including activity against
influenza A (Figure 2). In a recent SARS-CoV-2 screening
publication by Wang and co-workers, NTZ was somewhat
overlooked despite expressing a similar antiviral EC50 to
chloroquine. Here, we summarize and analyze the current
literature on NTZ, on which there is a large body of clinical
data, and related thiazolides with a recommendation that trials
of this agent either alone or in combination as a curative agent
for COVID-19 are warranted.
■ AN APPROVED CRYPTOSPORIDIUM DRUG WITH
BROAD ANTI-INFECTIVE SPECTRA
NTZ (4) was first synthesized in the early 1970s and is a
prototype of a class of compounds known as the
thiazolides.15,16 Its structure is based on the scaffold of the
anthelmintic niclosamide (5), which also displays broad
spectrum antiviral activity including against coronaviruses
(IC50 of 0.28 μM versus SARS-CoV-2) (Figure 2).
15,17,18 In
vivo, the active form of NTZ is known as tizoxanide (TIZ, 6)
(in vitro against SARS CoV-2 NTZ and TIZ have similar
potencies, vide infra) and together with niclosamide represent
the potential of salicylamide derivatives to be developed as a
class of compounds against SARS-CoV-2 (an overview of
niclosamide is outside the scope of this review).19
The main indication of NTZ is as an oral antiparasitic agent,
and it is registered in Latin America, Egypt, India, and
Bangladesh for the treatment of intestinal protozoa and
helminths. In addition to this, NTZ is FDA-approved in the
US for the treatment of diarrhea caused by Cryptosporidium
parvum and Giardia intestinalis.15 Today it remains the only
FDA-approved treatment for Cryptosporidium infections.15,16
Currently, NTZ is available orally both as a tablet (500 mg)
and in the form of a suspension (100 mg/5 mL) [Alinia-
Romark] for the treatment of adults and pediatric patients,
respectively.20,21 In addition to NTZ’s key role as an
antiparasitic, it has shown promising activity as a broad
spectrum antibacterial and antiviral agent (vide inf ra).22 Over
the years, NTZ has been involved in more than 40 clinical
trials across a broad range of drug targets, highlighting its
multifunctional chemotherapeutic significance.20
Reports of NTZ’s remarkable broad-spectrum antibacterial
activity first began to appear in the 1990s.23 Over the past two
decades, numerous studies and clinical trials have confirmed its
activity across a wide variety of both Gram-negative and Gram-
positive anaerobic bacteria.15 More recently, studies have
revealed its activity against Gram-positive aerobic bacteria such
as Mycobacterium tuberculosis, in addition to a number of
Gram-negative aerobes.15,24 There is great speculation
surrounding the mechanisms of action of NTZ. Both its
antiprotozoal and anaerobic antibacterial activity are believed
to be as a result of its ability to inhibit pyruvate:ferredoxin
oxidoreductase (PFOR), an enzyme essential for anaerobic
energy metabolism.15,25 In the case of aerobic bacteria there is
strong evidence to suggest that NTZ acts as an uncoupler,
disrupting membrane potential and intraorganism pH homeo-
stasis.15,26
It was also in the late 1990s that the antiviral activity of NTZ
was discovered by serendipity during its use in the treatment of
AIDS patients who had developed cryptosporidiosis.27 Since
then reports have emerged confirming its activity against a
broad range of both RNA and DNA viruses, including
influenza A, influenza B, respiratory syncytial virus, para-
influenza, coronavirus, rotavirus, norovirus, hepatitis B,
hepatitis C, dengue, yellow fever, Japanese encephalitis virus,
and human immunodeficiency virus.15,28,29 (see later section).
Overall, the oral bioavailability of the thiazolide class of
compounds is generally quite poor due to low aqueous
solubility.19 NTZ has an aqueous solubility of 0.0075 mg/mL
and an absolute oral bioavailability of just 3% in the rat.19−21
As a prodrug, NTZ is partially absorbed from the gastro-
intestinal tract and rapidly hydrolyzed into the active form of
Figure 1. Structures of remdesivir (1), chloroquine (2), and hydroxychloroquine (3).
Figure 2. Structures of nitazoxanide (NTZ) (4), niclosamide (5), tizoxanide (TIZ) (6) and tizoxanide glucuronide (TG) (6a).
Table 1. Physiochemical Properties of NTZ and TIZa
HBD HBA pKa
21,25 pKa (strongest acidic) pKa (strongest basic) LogP LogD LogS (pH 7.4) human protein binding (% bound)
15,30
NTZ 1 8 6.18 8.3 −4.2 2.322 2.322 2.601
TIZ 2 7 7.81 −4.2 2.157 2.157 2.85 >99.9
aValues for HBD, HBA, LogP, LogD, and LogS were calculated or predicted by StarDrop (version 6.5). Values for pKa (strongest acidic) and pKa
(strongest basic) were predicted by Chemaxon via DrugBank.20
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the drug, tizoxanide (TIZ, 6) (Figure 2),30 which is heavily
protein bound (Table 1).15 As a result, coadministration with
other highly protein bound drugs, such as warfarin, may be a
concern. A phase I study into the effect of NTZ on the
pharmacodynamics and pharmacokinetics of a single dose of
warfarin concluded it to be safe and well tolerated.31 It is not
fully understood as to how or why TIZ is so highly plasma
protein bound, but it is believed to primarily bind to albumins
due to being slightly acidic (Table 1).32
Over the past two decades NTZ has been subjected to
extensive pharmacological testing for its safety in both animals
and humans.15 Its use has been evaluated in a number of
clinical trials with only minor adverse effects such as diarrhea,
abdominal pain, headache, and nausea being reported at low
rates similar to placebo groups.33,34 Additionally, in vitro
metabolic studies have demonstrated that there is no
significant inhibitory effect on cytochrome P450 (CYP450)
enzymes; therefore no drug−drug interactions are expected.35
Overall, NTZ has an established safety profile, with one-time
oral doses of up to a remarkable 4 g shown to be safely
tolerated in healthy adult volunteers.36
■ THE ANTIVIRAL SPECTRA AND
ANTI-CORONAVIRUS ACTIVITIES OF NTZ: IN
VITRO, IN VIVO, AND CLINICAL
As noted, NTZ and its active metabolite, TIZ, along with
newer thiazolide analogues, have been shown to exhibit broad-
spectrum activity against a wide range of viruses.15,37,38 The
most significant indications have been those against intestinal
viruses, hepatitis, and influenza. Key in vitro and clinical data
for NTZ against these indications is summarized in Table 2
and Table 3 respectively. Other reports indicate significant in
vitro activity against a host of viral species as described
later.39−43
The antiviral activity of NTZ was first reported against
rotavirus by Rossignol et al. in 2006.44 This study included in
vitro assays of TIZ in cells infected with simian rotavirus SA-
11. It was found that TIZ inhibited rotavirus replication with
an EC50 of 1.9 μM and that this effect was sustained with
increasing viral load (Table 2). Also reported was a
randomized double-blind placebo-controlled trial of 50
children with rotavirus diarrhea who were treated with either
NTZ or placebo. NTZ treatment was shown to decrease the
median time to resolution of symptoms to 31 h, with no
adverse effects reported, compared to 75 h for the placebo
group (Table 3). Further clinical trials in adults demonstrated
that NTZ treatment significantly reduced the median time to
resolution of symptoms of both rotavirus and norovirus related
gastroenteritis to 1.5 days, compared to 2.5 days for placebo
(Table 3).45 The clinical findings were corroborated by further
in vitro studies against rotavirus,46 showing that NTZ and TIZ
inhibited viral replication in both the simian SA11-G3P
rotavirus (EC50 of 3.3 μM and 1.9 μM respectively) and
human Wa-G1P rotavirus (EC50 of 6.5 μM and 3.8 μM
respectively). Both compounds also demonstrated significant
cytoprotective effects in cells infected with rotavirus. Recent in
vitro studies have also confirmed the dose-dependent activity
of NTZ and TIZ against norovirus with no major cytotoxicity
observed.47
NTZ and TIZ are also active against hepatitis B virus
(HBV), inhibiting the production of both extracellular HBV
DNA (EC50 of 0.12 μM and 0.15 μM, respectively) and
intracellular HBV replicons (EC50 of 0.59 μM and 0.46 μM,
respectively) with good selectivity and low cytotoxicity.48
Similar results were obtained against replicating hepatitis C
virus (HCV), with EC50 values of 0.33 μM for NTZ and 0.25
μM against HCV genotype 1a.48 For both HBV and HCV,
antiviral activity was maintained across multiple genotypes
(Table 2). These results have been corroborated in later
screens along with novel thiazolide analogues.27,29 However, in
the case of HCV, other studies using alternative detection
methods (qRT-PCR) have not consistently replicated this in
vitro activity.49 Further studies also demonstrated that both
NTZ and TIZ possessed a high barrier to resistance by
HCV.50,51 A number of clinical trials have also been
conducted, investigating the efficacy of NTZ treatment of
both hepatitis B and C. Trials against hepatitis B have been
somewhat limited, comprising case reports52 and a small
Table 2. Summary of EC50, IC50, and IC90 Values for Key Indications of NTZ and TIZ
virus strain NTZ EC50 or IC50 (μM) TIZ EC50 or IC50 (μM) ref
rotavirus SA-11 3.3 1.9 Rossignol et al.,44 La Frazia et al.46
WA-G1P 6.5 3.8 La Frazia et al.46
hepatitis B wild-type 0.12,a 0.59b 0.15,a 0.46b Korba et al.48
hepatitis C genotype 1a 0.33 0.25 Korba et al.48
genotype 1b 0.21 0.15 Korba et al.48
1a, 1b, 2a, 4a 2.5 to >10.1 2.7 to >8.8 Khan et al.49
influenza A H1N1 A/PR/8/34 3.3 3.8 Rossignol et al.61
H1N1 A/WSN/33 1.6 1.9 Rossignol et al.61
H5N9 A/Ck/It/9097/97 3.3 1.9 Rossignol et al.61
H3N2v (4 variants) 0.88−18.3c Sleeman et al.62
H1N1 (54 variants) 0.13d Tilmanis et al.63
H3N2 (53 variants) 0.16d Tilmanis et al.63
influenza B Victoria lineage (47 variants) 0.18d Tilmanis et al.63
Yamagata lineage (56 variants) 0.16d Tilmanis et al.63
coronavirus CCov S-378 3.3 Rossignol15
murine coronavirus 3.3 Cao et al.70
MERS-CoV 3.0 3.1 Rossignol28
SARS-CoV-2 2.12 Wang et al.8
SARS-CoV-2 3.16−7.94 3.16 NIH71
aExtracellular virion DNA. bIntracellular HBV replication intermediates. cIC90 value.
dMedian value across multiple variants.
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ćh
ot
54
he
pa
tit
is
B
II
48
60
0
m
g
N
T
Z
on
ce
or
tw
ic
e
da
ily
,o
r
90
0
m
g
N
T
Z
tw
ic
e
da
ily
N
T
Z
vs
pl
ac
eb
o
in
pa
tie
nt
s
un
de
rg
oi
ng
tr
ea
tm
en
t
fo
r
ch
ro
ni
c
he
pa
tit
is
B
;
on
go
in
g
N
C
T
03
90
56
55
he
pa
tit
is
C
(g
en
ot
yp
e
4)
II
50
50
0
m
g
N
T
Z
tw
ic
e
da
ily
or
pl
ac
eb
o
ne
ga
tiv
e
se
ru
m
H
C
V
R
N
A
le
ve
ls
in
7
of
23
pa
tie
nt
s
in
N
T
Z
gr
ou
p,
0
of
24
in
pl
ac
eb
o.
Si
x
of
7
re
sp
on
de
rs
ac
hi
ev
ed
SV
R
c
R
os
si
gn
ol
et
al
.5
5
(N
C
T
00
41
86
39
)
he
pa
tit
is
C
(g
en
ot
yp
e
4)
II
96
50
0
m
g
N
T
Z
tw
ic
e
da
ily
+
IF
N
+
R
B
V
or
50
0
m
g
N
T
Z
tw
ic
e
da
ily
+
IF
N
SV
R
c
ac
hi
ev
ed
in
79
%
of
pa
tie
nt
s
in
N
T
Z
+
IF
N
+
R
B
V
gr
ou
p,
50
%
in
IF
N
+
R
B
V
on
ly
R
os
si
gn
ol
et
al
.5
6
(N
C
T
00
42
14
34
)
he
pa
tit
is
C
(m
ul
tip
le
ge
no
ty
pe
s)
II
44
50
0
m
g
N
T
Z
tw
ic
e
da
ily
+
IF
N
SV
R
c
ac
hi
ev
ed
in
80
%
of
pa
tie
nt
s
tr
ea
te
d
w
ith
N
T
Z
+
IF
N
+
R
B
V
R
os
si
gn
ol
et
al
.5
7
(N
C
T
00
76
35
68
)
he
pa
tit
is
C
(g
en
ot
yp
e
1)
II
64
d
50
0
m
g
N
T
Z
tw
ic
e
da
ily
+
IF
N
+
R
B
V
SV
R
c
ac
hi
ev
ed
in
7%
of
pa
tie
nt
s
tr
ea
te
d
w
ith
N
T
Z
+
IF
N
+
R
B
V
,
0%
fo
r
pl
ac
eb
o
+
IF
N
+
R
B
V
Sh
iff
m
an
et
al
.5
8
(N
C
T
00
49
53
91
)
he
pa
tit
is
C
(g
en
ot
yp
e
1)
II
11
2
50
0
m
g
N
T
Z
tw
ic
e
da
ily
+
IF
N
+
R
B
V
SV
R
c
ac
hi
ev
ed
in
44
%
of
pa
tie
nt
s
tr
ea
te
d
w
ith
N
T
Z
+
IF
N
+
R
B
V
,
32
%
fo
r
pl
ac
eb
o
+
IF
N
+
R
B
V
B
ac
on
et
al
.5
9
(N
C
T
00
63
79
23
)
he
pa
tit
is
C
(g
en
ot
yp
e
4)
II
I
10
0
50
0
m
g
N
T
Z
tw
ic
e
da
ily
+
IF
N
+
R
B
V
SV
R
c
ac
hi
ev
ed
in
50
%
of
pa
tie
nt
s
tr
ea
te
d
w
ith
N
T
Z
+
IF
N
+
R
B
V
,
48
%
w
ith
IF
N
+
R
B
V
Sh
eh
ab
et
al
.6
0
(N
C
T
01
27
67
56
)
in
fl
ue
nz
a
(u
nc
om
pl
ic
at
ed
)
II
/I
II
62
4
30
0
m
g
or
60
0
m
g
N
T
Z
tw
ic
e
da
ily
m
ed
ia
n
du
ra
tio
n
of
sy
m
pt
om
s:
95
.5
h
(6
00
m
g
N
T
Z
),
10
9.
1
h
(3
00
m
g
N
T
Z
),
11
6.
7
h
(p
la
ce
bo
)
H
affi
zu
lla
et
al
.6
8
(N
C
T
01
22
74
21
)
m
ul
tip
le
re
sp
ir
at
or
y
vi
ru
se
s
II
10
0b
10
0−
20
0
m
g
N
T
Z
tw
ic
e
da
ily
m
ed
ia
n
du
ra
tio
n
of
sy
m
pt
om
s:
4
da
ys
fo
r
N
T
Z
tr
ea
tm
en
t
vs
>7
da
ys
fo
r
pl
ac
eb
o
G
am
iñ
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clinical trial53,54 in adults with chronic hepatitis B (Table 3).
Across the two clinical trials, reductions of serum HBV DNA
to undetectable levels were observed in most patients (81%
overall), as well as several patients who initially tested positive
for hepatitis B e antigen (HBeAg) becoming HBeAg-negative
(5 out of 6 patients total) over the treatment period.
Furthermore, 29% of patients also tested negative for hepatitis
B surface antigen (HBsAg) at the end of treatment (Table 3).
Additional trials are ongoing to assess coadministration of
NTZ with existing regimens for treatment of chronic HBV
(NCT03905655) (Table 3). Clinical trials against hepatitis C
have demonstrated that NTZ has modest efficacy as a
monotherapy at the doses at which it has been tested,
achieving undetectable serum HCV RNA in 7 out of 23
patients in the treatment group compared to 0 of 24 in the
placebo group.55 Subsequent trials examined the effect of
coadministration of NTZ with Peginterferon alfa-2a (IFN) and
ribavirin (RBV) in various regimens in 96 patients with chronic
hepatitis C.56,57 The results indicated that NTZ coadminis-
tered with RBV and IFN increased the rate of rapid viral
response (64%) and sustained viral response (79%) compared
to RBV and IFN only (38% and 50%, respectively). Further,
two large trials (176 patients) demonstrated an increase in
sustained viral response for the combined treatment compared
to placebo plus RBV and IFN (7% and 44% for combined
treatment compared to 0% and 32% for placebo group).58,59
However, later clinical trials have failed to replicate these
results, reporting no benefit for the addition of NTZ to IFN
and RBV for treatment of hepatitis C.60
Influenza has become another important viral target for
NTZ, with early studies reporting significant in vitro activity of
both NTZ and TIZ against several strains of influenza A virus
(IAV) including H1N1, H3N2, and H5N9 (Table 2).61 This
study demonstrated that NTZ and TIZ exhibited dose-
dependent activity versus IAV in a variety of cell types, with
EC50 values of 1.7−5.7 μM (Table 2). NTZ was subsequently
tested against a panel of H3N2 IAV variants circulating in the
United States between 2011 and 2013,62 reporting slightly
higher activity with IC90 values between 1.1 and 5.7 μM. These
findings were expanded upon with a screen of 210 circulating
IAV and influenza B virus (IBV) strains against TIZ.63 The
results were in line with previous studies, with median EC50
values of 0.48 μM and 0.62 μM against H1N1 and H3N2 IAV
strains, respectively, and 0.66 μM and 0.60 μM against Victoria
lineage and Yamagata lineage IBV. Further in vitro studies
showed this activity was also present against canine influenza
virus with comparable potency (EC50 = 1.63 μM and 1.89 μM
for both NTZ and TIZ, respectively).64 In vitro studies with
oseltamivir and zanamivir have also demonstrated potential for
use of NTZ as a combination therapy.65 Once more, NTZ
demonstrated significant activity against a number of strains of
IAV (IC50 values between 1.0 and 3.2 μM) as well as
synergistic effects with both oseltamivir and zanamivir,
compared to individual administration of each compound.
NTZ has also emerged as one of 41 hits from a screen of 1280
compounds against IAV,66 as well as being identified in a
screen for potential protein disulfide isomerase inhibitors of
IAV/IBV.67 A number of clinical trials have been conducted
for NTZ treatment of influenza based on its significant in vitro
activity. A phase 2b/3 trial on 624 patients conducted in the
United States found that individuals with uncomplicated
influenza-like illness experienced a significant reduction in time
to alleviation of symptoms at high doses (median reduction of
21.2 h at 600 mg/day, Table 3) compared to placebo, although
the reduction at the lower dose (median reduction of 7.6 h at
300 mg/day) was not statistically significant.68 Trials in
children with influenza-like illness in Mexico (186 children
across 2 studies) demonstrated that NTZ treatment reduced
time to resolution of symptoms by 3 days.69 This was followed
by a trial in 257 patients who had been hospitalized with severe
influenza-like illness (caused by a variety of viruses including
influenza), which found no statistically significant reduction in
duration of hospital stay associated with NTZ plus standard of
care (including fluid replacement therapy, supplemental
oxygen, antivirals, and antibiotics) compared to placebo plus
standard of care.69 A number of further large phase 3 trials are
ongoing (NCT01610245, NCT02612922, NCT03336619) to
further determine the role of NTZ in influenza therapy.
Early testing of the antiviral properties of NTZ and other
analogues revealed high activity against canine coronavirus
(CCov, IC50 = 5.2−21.2 μM) among a wide range of other
coronaviruses (Table 2).15,38 Following the 2012 Middle East
respiratory syndrome (MERS) outbreak, screening of the NIH
clinical collection identified NTZ as a potent inhibitor of
murine coronavirus (IC50 = 3.3 μM, Table 2) and was
recommended as a potential therapy for the disease.70 Direct
screening of TIZ and NTZ against MERS-CoV also showed
high activity with IC50 values of 3.1 μM and 3.0 μM,
respectively.28 Most recently, NTZ was also reported to be
active against SAR-CoV-2 in vitro (see later section). In
general, TIZ showed either equal or slightly higher potency
than NTZ in most of the reported antiviral assays.
■ IN VITRO ACTIVITY OF NTZ AND ITS
METABOLITES AGAINST SARS-COV-2
Only one published paper to date has been reported by Wang
et al. for the in vitro activity of NTZ against SARS-CoV-2 with
no data for the major metabolite TIZ.8 The reported EC50 was
2.12 μM (0.651 μg/mL) for NTZ against SARS-CoV-2
(BetaCoV/Wuhan/WIV04/2019) in Vero E6 cells. In another
recent report,73 after reanalysis of the data from the same study
reported by Wang et al., the EC90 of NTZ was estimated as
4.65 μM (1.43 μg/mL). It is well documented in the literature
that NTZ is readily turned over to its active metabolite TIZ in
vivo (NTZ in vivo t1/2 ≤ 6 min) and NTZ is undetectable in
plasma.30 However, the turnover rates of NTZ to TIZ in vitro
could vary significantly under different temperature and pH
conditions, for example, the half-life of NTZ at 37 °C was 33 h
at pH 5 and only 3 h at pH 8. Under the assay conditions, it is
fair to say that the dynamic ratio of NTZ/TIZ within the
reported assay could lead to a misinterpretation of the in vitro
activity of either NTZ or TIZ against the virus in vitro. So, it is
critically important that the active metabolite, TIZ, is assessed
in any antiviral assay against SARS-CoV-2 to determine the
potency unambiguously. Most recently, from a non-peer-
reviewed source, the potency of TIZ against SARS-CoV-2 in
vitro (EC50 = 3.16 μM) was reported as similar to NTZ (EC50
= 3.16−7.94 μM) under the same assay conditions.71 These
data again confirmed that both NTZ and TIZ are active against
SARS-CoV-2 at a low micromolar range in vitro (we have
evaluated the antiviral activity independently at Liverpool with
EC50 values of 5.05 μM and 4.07 μM for NTZ and TIZ,
respectively, which ties in with literature observations (See
Supporting Information, Figure S1). Furthermore, as described
in the following section (Human PK analysis), tizoxanide
glucuronide (TG) (Figures 2, 6a), the major metabolite of
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TIZ, is another major circulating species metabolite after oral
administration of NTZ in human; the in vitro activity of TG
against the virus is yet another important factor to be
considered when considering the overall antiviral efficacy of
NTZ in humans but to date the activity of this metabolite has
not been formally measured.
■ MECHANISM OF ANTIVIRAL EFFECTS
With NTZ’s demonstrated efficacy and clinical utility against a
wide range of viral infections, its potential role in the treatment
of SARS-CoV-2 has come into focus. Studies into the mode of
action of NTZ within the different viral infections have
identified significant upregulation of innate immune responses
in many cases indicative of NTZ targeting one or more host
factors. Specific effects on the virus have also been identified
potentially due to secondary host immunomodulatory events
or even direct drug action. NTZ’s broad spectrum of antiviral
activity is indicative of the former, but further investigations
are required to definitively establish this (Figure 3). The
variability of nitazoxanide’s antiviral mode of action against
different viruses indicates that this area requires further studies
to clarify both mechanism and mode of action and to exclude
nonspecific effects, such as those caused by pan-assay-
interference (PAINS) properties.74,75 While nitazoxanide has
not been reported to act as an assay interference compound in
the literature, is inert in chemical reactivity screens, and is not
reported to be an aggregator,76 the unusually broad spectrum
of activity requires more definitive studies to define common
and differential targets against its target viruses.
As noted, NTZ is also known to have antiparasitic activity
against Giardia lamblia and Cryptosporidium parvum. NTZ is
the mainstay of proven treatment against Cryptosporidium
infections; however it is not effective in severely immunocom-
promised patients, further indicating NTZ’s role in immuno-
modulation of the host to impart pathogen clearance.77 While
the focus of this review is NTZ’s antiviral activity, this adds to
the weight of evidence toward the immunomodulatory mode
of action of NTZ. The disease specific information included
below summarizes what is known within the literature, but it
should be stressed that there is much that is still unknown.
In the case of influenza A, it has been shown through in vitro
cellular cultures (PR8-infected MDCK cells) that NTZ
mediates reduced maturation of viral hemagglutinin at the
post-translational stage after entry into the cell, between the
endoplasmic reticulum and the Golgi apparatus.15,16 Intra-
cellular transport and insertion into host plasma membrane are
both impaired as a result. NTZ has been shown to have no
effect on the other glycoprotein, neuraminidase, the target of
oseltamivir and zanamivir, or the M2 protein, the target of
amantadine, and it had no effect on viral infectivity, adsorption,
or entry into target cells as determined by in vitro studies
utilizing SA11-infected MA104 cells.46,61
NTZ also has effects in peripheral blood mononuclear cells
(PBMCs). PBMCs from 10 healthy donors were cultured in
the presence or absence of 3 different doses of TIZ (0.5, 1.0,
and 10 mg/mL) in both unstimulated and flu-stimulated
conditions and analyzed for T helper and cytotoxic T
lymphocyte (CTL) activity as well as for toll-like receptor 7
(TLR7) and TLR8 expression and type I interferon (IFN)
responses. NTZ potentiates the production of type 1
interferons (alpha and beta) produced by the host’s
fibroblasts.78 The full significance of this is not clearly defined,
but it may contribute to the antiviral activity of NTZ by
interfering with maturation of the hemagglutinin glycoprotein
as detailed above or as another secondary mechanism of
action. Similar effects have been seen during in vitro HIV-1
studies utilizing PBMCs from 20 healthy donors infected in
vitro with HIV-1BaL, where NTZ activates an innate immune
response with the up-regulation of several interferon-
stimulated genes (ISGs), including those involved in the
cholesterol pathway, particularly the cholesterol-25 hydrox-
ylase (CH25H). NTZ inhibition of HIV-1 replication in vitro
could be due to its ability to stimulate potent and multifaceted
antiviral immune responses.39,40,79 NTZ has also been shown
to decrease HIV-1 replication in monocyte-derived macro-
phages (MDMs) if present before or during HIV-1 infection.
This NTZ effect is associated with downregulation of HIV-1
receptors CD4 and CCR5 and increasing gene expression of
host cell anti-HIV resistance factors APOBEC3A/3G and
tetherin.
TIZ has been studied to ascertain its mode of action in
rotavirus. In vitro studies have demonstrated that TIZ inhibits
the maturation of rotavirus viral protein 7 (VP7, a glycoprotein
that forms the outer part of the virion and one of the six
structural glycoproteins involved in rotavirus replication),
alters viroplasm formation, and interferes with viral morpho-
genesis by hindering the interaction between the nonstructural
proteins NSP5 and NSP2.46
With HCV in cell cultures, TIZ has been shown to activate
protein kinase R (PKR). PKR plays an important role in the
innate immune response. PKR is activated in cells exposed to
double-stranded RNA, which subsequently results in phos-
Figure 3. Summary of viral modes of action of NTZ/TIZ.
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phorylation of eukaryotic initiation factor 2α (eIF2-α), a gene
known to block viral replication.53,80,81 TIZ therefore has the
potential to boost intracellular host antiviral activity.
In vitro studies using bovine viral diarrhea virus (BVDV) in
MDBK cells as a surrogate for HCV infection have shown that
NTZ inhibits replication of cytopathic and noncytopathic
BVDV by a mechanism that is likely to involve phosphor-
ylation of PKR and eIF2-α. NTZ was also found to deplete
ATP-sensitive intracellular Ca2+ stores resulting in mild
endoplasmic reticulum (ER) stress; this in turn disrupts N-
linked glycosylation of BVDV structural proteins.82 NTZ also
has been found to inhibit the HBx−DDB1 protein interaction
in HBV. Significant suppression of viral transcription and viral
protein production in the HBV minicircle system and in
human primary hepatocytes naturally infected with HBV was
noted.83 In addition, there are reports of NTZ and TIZ having
potential utility in the treatment of Ebola through broad
amplification of the host innate immune response to viruses
and subsequent suppression of Ebola virus replication as
demonstrated in vitro using multiple cell lines and genome
editing techniques. From an immune response perspective,
NTZ enhances multiple pathways including retinoic-acid-
inducible protein I (RIG-I)-like-receptor, mitochondrial
antiviral signaling protein, interferon regulatory factor 3, and
interferon activities and induces transcription of the antiviral
phosphatase GADD34. RIG-I plays a particularly important
role in the identification of cells infected by intracellular
pathogens and helps maintain host-cell integrity. NTZ
significantly inhibits Ebola replication in human cells through
its effects on RIG-I and PKR.84
Inhibition of the protease complex NS2B−NS3 is the target
for NTZ in Zika virus as determined by an in vitro screen to
identify orthosteric inhibitors that directly target flavivirus
NS2B−NS3 interactions. The complex plays an essential role
during flaviviral polyprotein processing and thus represents an
attractive drug target.85 Within Paramyxoviridae (PMV, a large
family of enveloped viruses including important human
pathogens such as measles, mumps, and respiratory syncytial
virus (RSV)) NTZ inhibits viral replication by targeting thiol
oxidoreductase ERp57 involved in the fusion protein folding
process as demonstrated using multiple in vitro techniques on
monkey kidney (AGMK) cells infected with Sendai virus
(SeV).86
More recently, studies have been undertaken into the role of
NTZ and TIZ in the treatment of the Middle East respiratory
syndrome coronavirus (MERS-CoV).28,70 NTZ inhibits the
production of pro-inflammatory cytokines TNF-α, IL-2, IL-4,
IL-5, IL-6, IL-8, and IL-10 in peripheral blood mononuclear
cells (PBMCs) and results in reduced viral protein
accumulation in cells, possibly due to inhibition of viral N
protein expression but further work is required to fully
ascertain this. While not yet studied in humans (current studies
have been completed in an in vivo mouse model and in mouse
macrophages), this data suggests that NTZ could potentially
improve outcomes in patients infected with MERS-CoV/
SARS-CoV-2 by suppressing overproduction of pro-inflamma-
tory cytokines, including IL-6.87 Further studies are required to
fully elucidate the mechanism of action of NTZ/TIZ against
coronaviruses, but the current knowledge clearly orients NTZ
toward a potential role in the treatment of SARS-CoV-2.
Figure 4. Comparison of simulated TIZ exposures at two doses with the in vitro potency of NTZ against SARS-CoV-2. Simulated plasma (red) and
lung (blue) exposures of TIZ after receiving 0.5 or 1.0 g, bid, dose of NTZ for 7 days. The dashed lines represent the in vitro EC50 (0.641 μg/mL)
and EC90 (1.43 μg/mL) levels. Simulation was based on fitting data reported in Stockis et al.
91 in fed volunteers to a one-compartment metabolite
formation model.
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■ NTZ PHARMACOKINETICS IN HUMAN AND
PREDICTED ACCUMULATION IN LUNG
NTZ (500 mg, twice daily for 3 days) was approved for the
treatment of diarrhea caused by Giardia lamblia or
Cryptosporidium parvum in adult patients. In reported off-
label uses for other indications, that is, Clostridioides dif f icile
infection88 or cryptosporidiosis-associated diarrhea in HIV-
infected patients,89 the dosage and regimen of NTZ was
increased to up to 1000 mg twice daily for 14 days at most.
There were a number of phase 1 clinical trials reported in the
literature with extensive pharmacokinetic data in human. For
example, in the paper by Stockis et al. published in 1996,90 the
first exploratory trial of a 500 mg single dose of NTZ in
humans was described along with some basic pharmacokinetic
findings of NTZ in humans, for example, the detectable species
in plasma is its metabolite, TIZ. Thus, all reported PK
parameters after single 500 mg oral dosing of NTZ, such as
Cmax (1.9 mg/L), Tmax (2−6 h), AUC (3.9−11.3 mg·h/L), and
terminal T1/2 (1.03−1.6 h) are based on TIZ concentrations in
plasma. Once formed, TIZ primarily undergoes glucuronida-
tion within the liver to form tizoxanide glucuronide (6a),
which is excreted in the urine and bile; TIZ itself is also found
to be eliminated from the body via the urine, bile, and feces.30
In 2002, two back-to-back publications both authored by
Stockis and co-workers reported the findings from a single
ascending dose (SAD) trial (1, 2, 3, and 4 g of NTZ dosed
orally) and a multiple ascending dose (MAD) trial (0.5 and 1
g, bid, for 7 days oral dosing of NTZ).36,91 All dosages (up to 4
g in a single dose) and one multiple dosing regimen (0.5 g, bid
for 7 days) were well tolerated with only mild adverse events.
There was increased frequency of GI side effects reported in
the 1 g bid, 7 days dosing group, but no significant changes to
other parameters, that is, ECGs, vital signs, and laboratory
tests. From the SAD trial, it was reported that (1) plasma
concentrations of both major metabolites (TIZ and TG)
increased largely in a linear correlation with the dose between
1 and 4 g and (2) the food effect is significant, approximately
doubling the bioavailability and the concentrations of both
metabolites in all dosing groups. At the highest (4 g) dosing
with food, the two metabolites, TIZ and TG, could reach Cmax
of 70 μg/mL (TIZ) and 59.6 μg/mL (TG) and AUC of 768
μg·h/mL (T) and 832 μg·h/mL (TG), although it was also
noted that at this dosing level the Tmax was delayed and the
apparent elimination rate was noticeably lower than in the
lower dosage level, particularly for the glucuronide metabolite.
From the MAD trial, it was observed that at 0.5 g bid dosing
level, the measured pharmacokinetic parameters of both
metabolites were similar to the single dosing at the same
level; on the other hand, at 1 g bid dosing, the bioavailability of
both metabolites was increased noticeably (50−70%),
compared with single dosing, which indicated significant
accumulation at repeat dosing at this level. Also, the report
data obtained from the MAD study gave further evidence of
the steady state of the exposure level of both metabolites,
Figure 5. NTZ and various lead thiazolides: Antiviral activity of representatives vs influenza A virus.
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which can be used in human PK modeling to provide a further
insight into PK profiles of NTZ at different dosing levels.
Using the pharmacokinetic data available in the public
domain, it is feasible to simulate the exposure of TIZ at two
dosing levels (0.5 and 1 g, bid) for 7 days (Figure 4). However,
there is very limited information available concerning the
partition of the major metabolites between systemic circulation
and specific organs, such as the lung. As a major site of
infection for SARS-CoV-2, the concentrations of the major
metabolites in the lung after oral dosing of NTZ should be
taken into consideration as a major contributing factor in the
prediction of the antiviral efficacy for the treatment or
prevention of COVID-19. In a recently published report,92 a
PBPK model was used to predict the partition ratios between
plasma and lung for a number of repurposing candidate drugs
for COVID-19. In combination of the simulation of repeat
dosing NTZ and the predicted lung/plasma partition ratio, we
can estimate the lung concentration of TIZ in comparison to
the in vitro potency of TIZ against SARS-CoV-2 at the
standard dosage (0.5 g, bid) and the elevated off-label dosage
(1.0 g, bid) as repeated doses for 7 days (Figure 4). While at
the highest off-label dose (1.0 g, bid) the simulated TIZ
exposure in both plasma and the lung can be maintained above
the in vitro EC90 for the majority of the dosing period. This
preliminary PK/PD analysis provides some evidence to
support the repurposing of NTZ for the treatment of
COVID-19. Ongoing animal PK studies at Liverpool are
aiming to define the pulmonary concentrations of nitazoxanide
after oral administration. Furthermore, based upon our dose
predictions for nitazoxanide,85 a trial involving a 1500 mg bid
dose of nitazoxanide has received funding from Unitaid and
approval from the independent scientific advisory board for
evaluation within a phase I/IIa study in the COVID19
platform trial known as AGILE (www.agiletrial.net).
A number of registered clinical trials (Please refer to Table 3
for a list of NTZ and COVID-19 related trials.)93 in several
countries (e.g., the U.S., Brazil, Mexico, South Africa, India and
Egypt etc.) related to NTZ will provide further evidence to
support the nitazoxanide repurposing effort; however, further
detailed investigation through PK/PD modeling, including
provision of in vitro activity of TIZ and its glucuronide against
SARS-CoV-2 in the most physiological relevant conditions
(selection of host cell line, assay media, and multiplicity of
infection, etc., could significantly affect the outcome of in vitro
antiviral activity for the same drug; this was observed and
analyzed in some recent reports73 concerning the in vitro
screening of SARS-CoV-2) and simulation of the concen-
trations of both metabolites in the lung at different dosages and
regimen will provide critical information to guide better design
of clinical trials and understanding of trial results.
■ THIAZOLIDE ANALOGUES: BRIEF OVERVIEW OF
LITERATURE EXAMPLES AND ANTIVIRAL SAR
With NTZ/TIZ demonstrating clear potential in treatment of
SARS-CoV-2, it is also important to consider the multiple
thiazolide analogues that are present within the literature as
they could facilitate improved SARS-CoV-2 therapy.
Figure 5 depicts antiviral potency of various thiazolides
versus the H1N1 strain of influenza A virus.16 Both NTZ and
RM4848 (8) are being evaluated versus HBV, the former is in
clinical trials, and the latter is in preclinical development. In
general, the IC50 values for the parent prodrug acetates, for
example, NTZ (4), RM5038 (7), and RM5021 (10), are
similar to their phenolic metabolites. This includes other
prodrug variants such as the tert-butyl amino prodrug (14)
listed in Figure 5. In terms of development status, RM5038
and RM5021 are currently being evaluated in animal
preclinical studies.
There are no reported SAR studies on analogues of
nitazoxanide where an attempt is made to tease out direct
antiviral versus host mediated effects in in vitro assays by
traditional medicinal chemistry, and so moving forward
phenotypic screening will remain key to expanding SAR in
this field. For potential future lead optimization chemistry
versus coronaviruses, SAR trends across other viruses provide
valuable informative data on starting points. With this in mind,
we have examined available data as a guide for future thiazolide
lead optimization campaigns. Currently, the SAR for NTZ/
TIZ’s antiviral activity is relatively limited and is summarized in
Figure 6 (with representatives included in Figure 5).
Functionalization of both the thiazole and phenyl rings has
been performed against hepatitis B, hepatitis C, and influenza
A.16,27,29 One significant difference between NTZ’s antiviral
versus its antibacterial activity is the importance of the nitro
group attached to the C5 position of the thiazole ring. Previous
SAR studies into NTZ’s anaerobic antibacterial activity have
shown the nitro group to be essential for activity, with deletion
or modification completely abolishing activity.94−96 One study
demonstrated the importance of the nitro group being a result
of its ability to be reduced into a hydroxylamine, forming a key
intermediate in its mechanism of action against anaerobes.94
Moreover, previous work evaluating the SAR of NTZ against
Mycobacterium tuberculosis has also shown that removal of the
nitro group results in inactivity.24
Conversely, a number of thiazolide analogues (Figure 5)
have shown the nitro group to not be essential for antiviral
activity. In particular, direct replacement of the nitro group
with other electron withdrawing substituents has provided
analogues with good antiviral activity. That the nitro group is
not essential for antiviral activity is significant since it rules out
a redox based mechanism of action (bioactivation by reduction
Figure 6. Antiviral SAR of NTZ/TIZ against influenza A, hepatitis B, and hepatitis C.
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and redox cycling) and increases the drug-like properties of the
thiazolide analogue. While nitazoxanide has been shown to be
a well-tolerated drug clinically, it is well evidenced that drugs
containing nitro groups can induce severe toxicity with the
nitro aromatic or heterocycle being classed as a metabolic alert.
Thus, analogues removing this liability while maintaining
potency will have a clear potential advantage.97
Overall, the antiviral SAR work carried out so far against
hepatitis B, hepatitis C, and influenza A has shown a clear
preference for electron withdrawing groups attached to not
only the C5 but also the C4 position of the thiazole ring.16,27,29
As shown in Figure 5, a significant improvement in influenza A
activity can be achieved with the incorporation of alkylsulfone
groups at the C4 position.16 Only two 4′,5′-disubstituted
analogues have been reported so far (4′-Me/5′-Br and 4′-Ph/
5′-Br), however both proved to be inactive against hepatitis
C.29
In addition to investigation of the thiazole ring, substitution
on the phenyl ring also has been of interest in determining the
overall antiviral SAR of NTZ/TIZ analogues. Methylation at
the different positions around the phenyl ring typically causes a
decrease in antiviral activity against influenza A.16 However, for
hepatitis B and C, methylation around the phenyl ring has a
much more varied effect on antiviral activity. Halogenation of
the phenyl ring has also been explored for hepatitis B and C.
Chlorination of TIZ and the 5′-Br analogue results in
moderate activity.27,29 Interestingly for influenza A, the para
hydroxy isomer of TIZ shows a 10-fold increase in activity.16
The free phenol, or its precursor the acetate (or other prodrug
ester), is essential for activity. Even methylation to the O-
methyl ether virtually abolishes all activity.98 It does appear
that a free NH and a free OH are both required for active
thiazolides.
■ SYNTHETIC CHEMISTRY OF NITAZOXANIDE,
PRODRUGS, AND IMPROVED THIAZOLIDES
One of the attractive features of NTZ and other thiazolides is
that a general synthesis is available for a wide range of
analogues starting from commercially available O-acetylsalicy-
loyl chloride by reaction with an appropriate 2-amino-5-
substituted thiazole. In the case of NTZ 4 itself, the use of
Et3N as base and THF as solvent is necessary; 2-amino-5-
nitrothiazole is poorly soluble and a weak nucleophile. In cases
where the aminothiazole is a better nucleophile, a two-phase
procedure, viz. CH2Cl2 or EtOAc/aq. NaHCO3, may be a
good and simple alternative. This is effective for the HCl salt of
2-amino-5-chlorothiazole, leading to the 5-Cl analogue 7 in
high yield. The Liverpool group studied many coupling
methods, for example, HATU and other uronium reagents,
which we have summarized previously.27,29
A related series of molecules are 4′-substituted thiazolides.
In general, 2-amino-4-X-thiazoles, with the exception of X = Ph
or Br/Cl, are not readily available, and multistep syntheses may
be required to access the corresponding thiazolides. An
important example is the 4′-ethylsulfonyl thiazolide 10,
which showed outstanding activity against an H1N1 strain of
influenza A virus, IC50 = 0.14 μM.
16 This analogue was
synthesized by a five-step route from bromoacetyl bromide 15
(Scheme 1).99
As noted, an important point when considering the potential
of NTZ as an antiviral is that it behaves in vivo as a prodrug for
the free phenol, TIZ (6); the acetate ester is readily cleaved by
esterases in the blood.36 A number of alternative acyl groups
have been studied, but none showed a significant advantage
over 4.27 If TIZ 6 itself is needed, the acetate in 4 may be
cleaved using mild acid (aq. HCl, 60 °C) or base (aq. NH3,
THF, 20 °C then HCl to pH 1). In regards to biological
screening, for any particular thiazolide, the acetate and free
phenol are essentially equiactive. The free phenol is invariably
the active circulating metabolite in vivo.
The human metabolism of thiazolides has been studied in
detail only for NTZ 4 and RM5038 7. Once the ester has been
cleaved, the majority of the circulating dose is cleared as the O-
glucuronide; O-sulfation is only a minor pathway. Compounds
4 and 7 are not significantly bioactivated by a panel of CYPs; it
appears that the electron-withdrawing substituent at C(5)
prevents oxidative metabolism.30 It has yet to be determined
whether a 4′-electron withdrawing substituent as in 10 is
equally effective. By contrast, 4,5-unsubstituted thiazoles are
typically CYP-oxidized leading to toxic thiourea metabo-
lites.100,101
The solubilities of the thiazolides, especially as the free
phenols, are not optimal for good systemic absorption for the
treatment of respiratory viruses. One widely used method of
improving the oral absorption of a number of drugs is the use
of a pro-drug ester. A relevant example is the valine derivative
valcyclovir 20,102,103 which increases the oral absorption of its
parent, the antiviral agent acyclovir, 21 from 20% to 54%. A
similar amino-acid derivative of TIZ (14) (Figure 5), expected
to show superior solubility and bioavailability to the acetate
esters NTZ 4 and 7, has been prepared and is currently
undergoing investigation.19
While it appears that thiazolides discussed in this review
(e.g. NTZ and RM5038/4848) can both affect terminal
glycosylation and transport of viral hemagglutinin to the cell
plasma-membrane, additional studies on analogues have not
been performed to correlate this activity with measured
Scheme 1. Synthesis of a 4′-(Ethylsulfonyl)thiazolea
aConditions and yields (i) NaSEt, Et2O, 86%; (ii) BocNHCSNH2 10,
iPrOH, 4 Å MS, 55%; (iii) dil. TFA, CH2Cl2, then aq. NaHCO3, extract with
Et2O, 96%; (iv) O-acetylsalicyloyl chloride, CH2Cl2, NMM, 81%; (v) mCPBA (2.2 equiv), CH2Cl2, 95%.
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antiviral effect in culture, and this will be important in future
target validation studies. Another aspect of research that
should follow would be to examine the propensity of an
analogue series to affect key host factors. Very recent studies
have demonstrated that NTZ inhibits host ERp57 activity,
causing newly synthesized F-protein misfolding and F-
aggregate formation and halting F-trafficking to the host
plasma membrane. Additional studies in multiple viruses
implicate additional host targets, but to date there are no
SARs to relate drug structure to function in these host
mediated effects; again this should be the subject of additional
research.
■ CONCLUSIONS
NTZ has a broad spectrum of anti-infective activity mediated
through modulation of host innate immune responses as well
as direct activity against multiple viral targets. NTZ has been
shown to improve clinical outcome when used against multiple
respiratory viruses and has been shown to have in vitro activity
against the coronaviruses, including SARS-CoV-2. This,
combined with its ease of synthesis, established human
pharmacokinetics, favorable preliminary PK/PD simulations
of plasma and lung accumulation, and extensive pharmaco-
logical safety testing in both animals and humans highlights the
therapeutic potential of NTZ.
While there are still questions to be answered with respect to
the mode of action of NTZ within SARS-CoV-2, the utility of
thiazolide analogues and pro-drugs, and more detailed PK/PD
modeling in order to inform further clinical trials, NTZ and its
second generation thiazolides without doubt have the potential
to be appropriate choices for repurposing versus SARS-CoV-2
either as monotherapy or as part of combinations. With
combination therapy in mind Bobrowski and co-workers have
completed a very recent in silico guided in vitro analysis of
possible drug combinations for SARS CoV-2.104 From the 16
synergistic cases, combinations of nitazoxanide with three
other compounds (remdesivir, amodiaquine, and umifenovir)
were the most notable, all exhibiting significant synergy against
SARS-CoV-2. Based on this observation, it would seem logical
to consider clinical trials of remdesivir with nitazoxanide given
the FDA approval of the former for use in COVID-19
infection. Using our online drug−drug interactions tool, we
would not expect any significant drug−drug interactions
between remdesivir and nitazoxanide.105 Clearly, to realize
the full potential of NTZ against COVID-19, further
assessments of safety and efficacy at current and elevated
doses should be investigated in ongoing and future clinical
trials.106,107
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Leyva, J. C. (2017) Physicochemical characterization of two new
Nitazoxanide analogs with antiparasitic activity. Med. Chem. Res. 26
(1), 9−18.
(22) Singh, N., and Narayan, S. (2011) Nitazoxanide: A Broad
Spectrum Antimicrobial. Medical Journal Armed Forces India 67 (1),
67−68.
(23) Dubreuil, L., Houcke, I., Mouton, Y., and Rossignol, J. F.
(1996) In vitro evaluation of activities of nitazoxanide and tizoxanide
against anaerobes and aerobic organisms. Antimicrob. Agents Chemo-
ther. 40 (10), 2266−2270.
(24) Odingo, J., Bailey, M. A., Files, M., Early, J. V., Alling, T.,
Dennison, D., Bowman, J., Dalai, S., Kumar, N., Cramer, J.,
Masquelin, T., Hipskind, P. A., and Parish, T. (2017) In Vitro
Evaluation of Novel Nitazoxanide Derivatives against Mycobacterium
tuberculosis. ACS Omega 2 (9), 5873−5890.
(25) Hoffman, P. S., Sisson, G., Croxen, M. A., Welch, K., Harman,
W. D., Cremades, N., and Morash, M. G. (2007) Antiparasitic drug
nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter
pylori, selected anaerobic bacteria and parasites, and Campylobacter
jejuni. Antimicrob. Agents Chemother. 51 (3), 868−876.
(26) de Carvalho, L. P. S., Darby, C. M., Rhee, K. Y., and Nathan, C.
(2011) Nitazoxanide Disrupts Membrane Potential and Intrabacterial
pH Homeostasis of Mycobacterium tuberculosis. ACS Med. Chem.
Lett. 2 (11), 849−854.
(27) Stachulski, A. V., Pidathala, C., Row, E. C., Sharma, R., Berry,
N. G., Iqbal, M., Bentley, J., Allman, S. A., Edwards, G., Helm, A.,
Hellier, J., Korba, B. E., Semple, J. E., and Rossignol, J.-F. (2011)
Thiazolides as novel antiviral agents. 1. Inhibition of hepatitis B virus
replication. J. Med. Chem. 54 (12), 4119−4132.
(28) Rossignol, J.-F. (2016) Nitazoxanide, a new drug candidate for
the treatment of Middle East respiratory syndrome coronavirus.
Journal of Infection and Public Health 9 (3), 227−230.
(29) Stachulski, A. V., Pidathala, C., Row, E. C., Sharma, R., Berry,
N. G., Lawrenson, A. S., Moores, S. L., Iqbal, M., Bentley, J., Allman,
S. A., Edwards, G., Helm, A., Hellier, J., Korba, B. E., Semple, J. E.,
and Rossignol, J.-F. (2011) Thiazolides as Novel Antiviral Agents. 2.
Inhibition of Hepatitis C Virus Replication. J. Med. Chem. 54 (24),
8670−8680.
(30) Broekhuysen, J., Stockis, A., Lins, R. L., De Graeve, J., and
Rossignol, J. F. (2000) Nitazoxanide: pharmacokinetics and
metabolism in man. Int. J. Clin. Pharmacol. Ther. 38 (8), 387−394.
(31) Vets, E., Rossignol, J.-F., and Jackson, A. S. (2009) Effects of
nitazoxanide on pharmacokinetics and pharmacodynamics of a single
dose of warfarin. Am. J. Health-Syst. Pharm. 66 (9), 838−842.
(32) Zhao, Z., Xue, F., Zhang, L., Zhang, K., Fei, C., Zheng, W.,
Wang, X., Wang, M., Zhao, Z., and Meng, X. (2010) The
pharmacokinetics of nitazoxanide active metabolite (tizoxanide) in
ACS Infectious Diseases pubs.acs.org/journal/aidcbc Review
https://dx.doi.org/10.1021/acsinfecdis.0c00478
ACS Infect. Dis. XXXX, XXX, XXX−XXX
L
goats and its protein binding ability in vitro. J. Vet. Pharmacol. Ther. 33
(2), 147−153.
(33) Rossignol, J. F., Ayoub, A., and Ayers, M. S. (2001) Treatment
of Diarrhea Caused by Giardia intestinalis and Entamoeba histolytica
or E. dispar: A Randomized, Double-Blind, Placebo-Controlled Study
of Nitazoxanide. J. Infect. Dis. 184 (3), 381−384.
(34) Keeffe, E. B., and Rossignol, J.-F. (2009) Treatment of chronic
viral hepatitis with nitazoxanide and second generation thiazolides.
World J. Gastroenterol. 15 (15), 1805−1808.
(35) Ramos-Soriano, A. G., and Black, J. (2015) Nitazoxanide Use as
Part of an Empiric Multi-Drug Regimen in Treating Children with
Suspected Helicobacter pylori Infection. Case Rep. Gastroenterol. 9
(1), 36−42.
(36) Stockis, A., Allemon, A. M., De Bruyn, S., and Gengler, C.
(2002) Nitazoxanide pharmacokinetics and tolerability in man using
single ascending oral doses. Int. J. Clin. Pharmacol. Ther. 40 (5), 213−
20.
(37) Rossignol, J.-F. (2009) Thiazolides: a new class of antiviral
drugs. Expert Opin. Drug Metab. Toxicol. 5 (6), 667−674.
(38) Santoro, M. G., Ciucci, A., Gianferretti, P., Belardo, G., La
Frazia, S., Carta, S., and Rossignol, J.-F. (2007) Thiazolides: A New
Class of Broad-Spectrum Antiviral Drugs Targeting Virus Maturation.
Antiviral Res. 74 (3), A31.
(39) Gekonge, B., Bardin, M. C., and Montaner, L. J. (2015) Short
communication: Nitazoxanide inhibits HIV viral replication in
monocyte-derived macrophages. AIDS Res. Hum. Retroviruses 31
(2), 237−241.
(40) Trabattoni, D., Gnudi, F., Ibba, S. V., Saulle, I., Agostini, S.,
Masetti, M., Biasin, M., Rossignol, J.-F., and Clerici, M. (2016)
Thiazolides Elicit Anti-Viral Innate Immunity and Reduce HIV
Replication. Sci. Rep. 6 (1), 27148.
(41) Shi, Z., Wei, J., Deng, X., Li, S., Qiu, Y., Shao, D., Li, B., Zhang,
K., Xue, F., Wang, X., and Ma, Z. (2014) Nitazoxanide inhibits the
replication of Japanese encephalitis virus in cultured cells and in a
mouse model. Virol. J. 11, 10.
(42) Wang, Y.-M., Lu, J.-W., Lin, C.-C., Chin, Y.-F., Wu, T.-Y., Lin,
L.-I., Lai, Z.-Z., Kuo, S.-C., and Ho, Y.-J. (2016) Antiviral activities of
niclosamide and nitazoxanide against chikungunya virus entry and
transmission. Antiviral Res. 135, 81−90.
(43) Perelygina, L., Hautala, T., Seppan̈en, M., Adebayo, A., Sullivan,
K. E., and Icenogle, J. (2017) Inhibition of rubella virus replication by
the broad-spectrum drug nitazoxanide in cell culture and in a patient
with a primary immune deficiency. Antiviral Res. 147, 58−66.
(44) Rossignol, J.-F., Abu-Zekry, M., Hussein, A., and Santoro, M. G.
(2006) Effect of nitazoxanide for treatment of severe rotavirus
diarrhoea: randomised double-blind placebo-controlled trial. Lancet
368 (9530), 124−129.
(45) Rossignol, J.-F., and El-Gohary, Y. M. (2006) Nitazoxanide in
the treatment of viral gastroenteritis: a randomized double-blind
placebo-controlled clinical trial. Aliment. Pharmacol. Ther. 24 (10),
1423−1430.
(46) La Frazia, S., Ciucci, A., Arnoldi, F., Coira, M., Gianferretti, P.,
Angelini, M., Belardo, G., Burrone, O. R., Rossignol, J.-F., and
Santoro, M. G. (2013) Thiazolides, a New Class of Antiviral Agents
Effective against Rotavirus Infection, Target Viral Morphogenesis,
Inhibiting Viroplasm Formation. J. Virol. 87 (20), 11096−11106.
(47) Dang, W., Xu, L., Ma, B., Chen, S., Yin, Y., Chang, K.-O.,
Peppelenbosch, M. P., and Pan, Q. (2018) Nitazoxanide Inhibits
Human Norovirus Replication and Synergizes with Ribavirin by
Activation of Cellular Antiviral Response. Antimicrob. Agents Chemo-
ther. 62 (11), No. e00707-18.
(48) Korba, B. E., Montero, A. B., Farrar, K., Gaye, K., Mukerjee, S.,
Ayers, M. S., and Rossignol, J.-F. (2008) Nitazoxanide, tizoxanide and
other thiazolides are potent inhibitors of hepatitis B virus and
hepatitis C virus replication. Antiviral Res. 77 (1), 56−63.
(49) Khan, H., Paeshuyse, J., Murad, S., and Neyts, J. (2016)
Assessment of the activity of directly acting antivirals and other
products against different genotypes of hepatitis C virus prevalent in
resource-poor countries. Antiviral Res. 125, 43−45.
(50) Yon, C., Viswanathan, P., Rossignol, J.-F., and Korba, B. (2011)
Mutations in HCV non-structural genes do not contribute to
resistance to nitazoxanide in replicon-containing cells. Antiviral Res.
91 (3), 233−240.
(51) Korba, B. E., Elazar, M., Lui, P., Rossignol, J.-F., and Glenn, J. S.
(2008) Potential for Hepatitis C Virus Resistance to Nitazoxanide or
Tizoxanide. Antimicrob. Agents Chemother. 52 (11), 4069−4071.
(52) Kolozsi, W., El-Gohary, Y., Keeffe, E., and Rossignol, J.-F.
(2008) Treatment of Chronic Hepatitis B (CHB) with Nitazoxanide
(Ntz) Alone or Ntz Plus Adefovir (ADV) for Two Years with Loss of
Hepatitis B E Antigen (HBeAg) and Hepatitis B Surface Antigen
(HbsAg): Report of Two Cases: 390. Am. J. Gastroenterol. 103, S150−
S151.
(53) Rossignol, J.-F., and Keeffe, E. B. (2008) Thiazolides: a new
class of drugs for the treatment of chronic hepatitis B and C. Future
Microbiol. 3 (5), 539−545.
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